divisun 2000 iu tabletti
viatris oy - cholecalciferol concentrate (powder form) - tabletti - 2000 iu - kolekalsiferoli (vitamiini d3)
duphagol 13.8 g jauhe oraaliliuosta varten
viatris oy - potassium chloride, sodium hydrogen carbonate, macrogol 3350, sodium chloride - jauhe oraaliliuosta varten - 13.8 g - makrogoli
duphagol junior 6.9 g jauhe oraaliliuosta varten
viatris oy - potassium chloride, sodium hydrogen carbonate, macrogol 3350, sodium chloride - jauhe oraaliliuosta varten - 6.9 g - makrogoli
zyx eukalyptus 3 mg imeskelytabletti
viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini
creon 20 000 enterokapseli, kova
viatris oy - pancreas powder - enterokapseli, kova - useita entsyymejä (lipaasi
creon 35 000 enterokapseli, kova
viatris oy - pancreas powder - enterokapseli, kova - useita entsyymejä (lipaasi
femke 30 mg tabletti, kalvopäällysteinen
viatris limited - ulipristal acetate - tabletti, kalvopäällysteinen - 30 mg - ulipristaali
influvac tetra 15/15/15/15 µg/annos injektioneste, suspensio, esitäytetty ruisku
viatris oy - influenza a virus h3n2, live, attenuated, influenza b virus, live, attenuated, influenza a virus h1n1, live, attenuated, influenza b virus, live, attenuated, victoria lineage - injektioneste, suspensio, esitäytetty ruisku - 15/15/15/15 µg/annos - influenssarokote
zyx appelsiini & hunaja 3 mg imeskelytabletti
viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroksabaani - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboottiset aineet - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.